BioCryst Pharmaceuticals BCRX Non-cash interest expense on royalty financing obligations
Non-cash interest expense on royalty financing obligations at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:NonCashInterestExpenseOnRoyaltyFinancingLiabilities.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations?
- BioCryst Pharmaceuticals (BCRX) reported non-cash interest expense on royalty financing obligations of $13.29M in Q1 2026.
- How has BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations changed year-over-year?
- BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations decreased by 1.6% year-over-year, from $13.51M to $13.29M.
- What is the long-term trend for BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's non-cash interest expense on royalty financing obligations has grown at a -11.4% compound annual growth rate (CAGR), from $76.48M to $53.16M.
- What does non-cash interest expense on royalty financing obligations mean?
- Represents the non-cash interest expense accrued on obligations tied to future royalty streams. This metric reflects the cost of capital associated with financing arrangements where repayment is linked to product revenue performance rather than fixed debt schedules.